| Quarter | Holdings | Value ($000) | Top Holdings | Form Type | Date Filed | Filing ID |
|---|---|---|---|---|---|---|
| Q1 2025 | 3 | 13,637 | KYTX, ALLO, KRON | 13F-HR | 4/3/2025 | 000095012325003299 |
| Q4 2024 | 6 | 146,329 | CNTA, TECX, KYTX, DYN | 13F-HR | 1/21/2025 | 000095012325000395 |
| Q3 2024 | 6 | 138,598 | CNTA, TECX, KYTX, DYN | 13F-HR | 10/8/2024 | 000095012324009559 |
| Q2 2024 | 5 | 91,433 | CNTA, KYTX, DYN, ALLO | 13F-HR | 7/10/2024 | 000095012324006464 |
| Q1 2024 | 5 | 180,005 | Kyverna Therapeutics, Inc., CNTA, DYN, ALLO | 13F-HR | 4/12/2024 | 000095012324003271 |
| Q4 2023 | 7 | 83,997 | CNTA, DYN, LIAN, ALLO | 13F-HR | 1/5/2024 | 000095012324000049 |
| Q3 2023 | 8 | 64,604 | CNTA, DYN, ALLO, KRON | 13F-HR | 10/3/2023 | 000095012323008652 |
| Q2 2023 | 7 | 76,589 | DYN, CNTA, ALLO, KNTE | 13F-HR | 7/19/2023 | 000095012323006173 |
| Q1 2023 | 7 | 73,092 | DYN, CNTA, KNTE, ALLO | 13F-HR | 4/13/2023 | 000095012323003235 |
| Q4 2022 | 7 | 74,416 | DYN, KNTE, CNTA, ALLO | 13F-HR | 2/8/2023 | 000095012323001109 |
| Q3 2022 | 8 | 111,423 | DYN, KNTE, ALLO, CNTA | 13F-HR | 10/5/2022 | 000095012322010047 |
| Q2 2022 | 8 | 118,342 | KNTE, ALLO, DYN, CNTA | 13F-HR | 7/15/2022 | 000095012322007224 |
| Q1 2022 | 8 | 171,934 | CNTA, KNTE, PRAX, DYN | 13F-HR | 5/4/2022 | 000095012322004532 |
| Q4 2021 | 8 | 267,331 | PRAX, KNTE, CNTA, KRON | 13F-HR | 2/10/2022 | 000095012322001712 |
| Q3 2021 | 8 | 349,152 | CNTA, KNTE, KRON, PRAX | 13F-HR | 11/12/2021 | 000095012321014994 |
| Q2 2021 | 9 | 398,837 | CNTA, KRON, KNTE, DYN | 13F-HR | 8/12/2021 | 000095012321010554 |
| Q1 2021 | 8 | 395,842 | PRAX, KNTE, KRON, ALLO | 13F-HR | 5/11/2021 | 000095012321005858 |
| Q4 2020 | 8 | 487,225 | PRAX, KNTE, KRON, DYN | 13F-HR | 2/12/2021 | 000095012321002036 |
| Q3 2020 | 5 | 159,652 | ALLO, DYN, OYST, FIXX | 13F-HR | 11/12/2020 | 000095012320011531 |